Stockscreener 앱 받기
1.655
12.23%
-0.225
전일 마감가:
$1.88
열려 있는:
$1.96
하루 거래량:
265.34K
Relative Volume:
3.77
시가총액:
$7.49M
수익:
-
순이익/손실:
$-31.88M
주가수익비율:
-2.2067
EPS:
-0.75
순현금흐름:
$-25.20M
1주 성능:
-21.43%
1개월 성능:
-30.96%
6개월 성능:
-67.55%
1년 성능:
-81.95%
1일 변동 폭
$1.54
$2.14
1주일 범위
$1.54
$2.14
52주 변동 폭
$1.54
$12.53
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.65 | 8.53M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.52 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
626.68 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.19 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.00 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.24 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Cabaletta Bio (Nasdaq: CABA) offers webcasts across Nov–Dec conferences; 30-day replays - Stock Titan
Gossamer Bio Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
[Form 3] TELA Bio, Inc. Initial Statement of Beneficial Ownership - Stock Titan
[8-K] TELA Bio, Inc. Reports Material Event | TELA SEC FilingForm 8-K - Stock Titan
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 85.8% in October - Defense World
[8-K] Inmune Bio, Inc. Reports Material Event | INMB SEC FilingForm 8-K - Stock Titan
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site - GlobeNewswire Inc.
Cabaletta Bio, Inc. Updates on Rese-cel Clinical Trials and FDA Alignment - TradingView
[8-K] Cabaletta Bio, Inc. Reports Material Event | CABA SEC FilingForm 8-K - Stock Titan
ANVS prices registered direct; directors buy 1.07M shares at $2.05 - Stock Titan
INMB to discuss Q3 2025 results on Oct 30, 4:30 p.m. ET - Stock Titan
Tourmaline Bio Announces Board and Executive Resignations Following Merger - TradingView
[8-K] Tourmaline Bio, Inc. Reports Material Event | TRML SEC FilingForm 8-K - Stock Titan
Why Nuvation Bio Inc. stock is a must watch in 2025Trade Entry Report & Long-Term Safe Investment Ideas - fcp.pa.gov.br
Cabaletta Bio, Inc. Presents Clinical Data and Updates at ACR Convergence 2025 - TradingView
INmune Bio (NASDAQ: INMB) schedules results call for 4:30 PM ET on Oct 30 - Stock Titan
[8-K] PALISADE BIO, INC. Reports Material Event | PALI SEC FilingForm 8-K - Stock Titan
Q32 Bio Inc Completes Enrollment in SIGNAL-AA Phase 2a Trial - TradingView
[8-K] bioAffinity Technologies, Inc. Reports Material Event | BIAF SEC FilingForm 8-K - Stock Titan
PALI annual meeting: directors elected, auditor ratified, split approved - Stock Titan
Stop Loss: Why Nuvation Bio Inc. stock is popular among millennials2025 Sector Review & Breakout Confirmation Alerts - Trung tâm Dự báo KTTV quốc gia
Samsung to invest $110 mn in Grail to bring early-cancer test to Asia - KED Global
Climb Bio Publishes Long-Term Data on Budoprutug - TradingView
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 - Stock Titan
CLYM reports budoprutug Phase 1b follow-up: 3-year control in 4 pts - Stock Titan
Palisade Bio Provides Corporate and Compliance Update - TradingView
PALI back in Nasdaq bid-price compliance; 133.0M shares out - Stock Titan
ANVS prices $6.0M offering; adds pre-funded and agent warrants - Stock Titan
[8-K] – Inmune Bio, Inc. (INMB) (CIK 0001711754) - Stock Titan
Inmune Bio Inc Announces Participation in Dermatologic Panel - TradingView
Oct 22 CEO Panel: INmune Bio's CORDStrom for RDEB — David Moss at Maxim Growth Summit in NYC - Stock Titan
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership - Reuters
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewswire
Is Mustang Bio Inc. stock ready for a breakoutJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
OrbiMed Funds Buy into Adicet Bio Offering; Ownership Diluted to 9.6% - Stock Titan
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
TELA insider award: 11,925 RSUs; option for 17,550 shares at $1.48 - Stock Titan
Korro Bio, Inc. (KRRO) Stock Price, News, Quote & History - Yahoo
TELA (TELA) Initial Form 3 — Director Records Zero Holdings - Stock Titan
Palisade Bio, Inc. Cancels Special Meeting of Stockholders - TradingView
[SCHEDULE 13G] PALISADE BIO, INC. SEC Filing - Stock Titan
Perceptive Discloses 9.99% Stake in Palisade Bio (12.24M Shares) - Stock Titan
Special Meeting Cancelled: Palisade Bio Withdraws Proxy Proposals After Failing to Secure Quorum - Stock Titan
PALI grants 7,665,800 RSUs to Chief Medical Officer; vesting over 2 years - Stock Titan
PALI Form 4: 9.18M RSUs granted to director/officer - Stock Titan
Bio, semiconductor, content firms to reboot Korea’s IPO market - KED Global
Commodore Capital and principals disclose 9.9% holding in PALI - Stock Titan
Deep Track discloses 6.43M pre-funded warrants, holds 9.99% of PALI - Stock Titan
Nuvation Bio Inc. (NUVB): A Bull Case Theory - Insider Monkey
PlayStation sale round-up for North America October 8, 2025 - TrueTrophies
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $8.50 - Defense World
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
0.56%
자본화:
|
볼륨(24시간):